Sepio Capital LP Reduces Holdings in Envista Holdings Co. (NYSE:NVST)

Sepio Capital LP lowered its stake in Envista Holdings Co. (NYSE:NVST) by 23.0% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 38,800 shares of the company’s stock after selling 11,619 shares during the period. Sepio Capital LP’s holdings in Envista were worth $748,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of NVST. Bryce Point Capital LLC acquired a new stake in shares of Envista during the 4th quarter worth about $590,000. Massachusetts Financial Services Co. MA lifted its stake in shares of Envista by 9.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,271,175 shares of the company’s stock valued at $63,101,000 after buying an additional 283,415 shares during the period. Trexquant Investment LP purchased a new position in shares of Envista during the fourth quarter valued at approximately $5,982,000. Franklin Resources Inc. boosted its position in Envista by 72.6% during the fourth quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company’s stock worth $132,223,000 after acquiring an additional 2,882,844 shares during the last quarter. Finally, California Public Employees Retirement System grew its stake in Envista by 0.4% in the 4th quarter. California Public Employees Retirement System now owns 288,546 shares of the company’s stock worth $5,566,000 after acquiring an additional 1,272 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on NVST shares. Piper Sandler increased their price target on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Morgan Stanley decreased their price target on Envista from $20.00 to $19.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 6th. JPMorgan Chase & Co. dropped their price objective on shares of Envista from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Thursday, March 6th. New Street Research set a $19.00 target price on shares of Envista in a research report on Thursday, March 6th. Finally, UBS Group dropped their price target on shares of Envista from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Monday, March 10th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Envista currently has an average rating of “Hold” and an average target price of $20.18.

Envista Stock Down 3.9 %

Shares of Envista stock opened at $15.47 on Monday. Envista Holdings Co. has a twelve month low of $14.77 and a twelve month high of $23.00. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of -2.38, a price-to-earnings-growth ratio of 1.27 and a beta of 1.12. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44. The company has a fifty day moving average price of $19.18 and a 200 day moving average price of $19.53.

Envista (NYSE:NVST) last posted its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Equities research analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current fiscal year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.